Hydroxyzine Hydrochloride Solution
NDC Package 72888-218-13
Package Information
Hydroxyzine Hydrochloride solution is for symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested.Useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses, and in histamine-mediated pruritus.As a sedative when used as premedication and following general anaesthesia, hydroxyzine may potentiate meperidine and barbiturates, so their use in pre- anesthetic adjunctive therapy should be modified on an individual basis. This formulation utilizes a solution delivery system. Marketed by Advagen Pharma Limited, this product is identified by NDC 72888-218 and is authorized under FDA application ANDA219561.
Identification & Billing
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 72888 - Advagen Pharma Limited
- 72888-218 - Hydroxyzine Hydrochloride
- 72888-218-13 - 473 mL in 1 BOTTLE
- 72888-218 - Hydroxyzine Hydrochloride
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 72888-218-13 identifies a specific commercial package of 473 ml in 1 bottle of Hydroxyzine Hydrochloride, a human prescription drug labeled by Advagen Pharma Limited. This solution is formulated for oral use and contains hydroxyzine hydrochloride as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Advagen Pharma Limited on September 11, 2026. The current certification is valid through December 31, 2027.
How is this Advagen Pharma Limited product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 72888021813. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.